Table 2 Proportional hazards regression for time to death

Gender (male versus female)

1.53 (1.40-1.68)

<0.001

1.43 (1.31-1.57)

<0.001

Age

14-19

1.00

1.00

20-29

0.98 (0.67-1.42)

0.895

1.05 (0.72-1.53)

0.794

30-39

0.90 (0.62-1.29)

0.566

0.96 (0.67-1.39)

0.835

40-49

0.87 (0.60-1.26)

0.459

0.93 (0.65-1.35)

0.713

50+

1.20 (0.82-1.75)

0.338

1.31 (0.90-1.91)

0.164

CD4 at antiretroviral therapy initiation (per 100 cells/mm³)

0.65 (0.61-0.68)

<0.001

CD4 count

<50

1.00

1.00

50-99

0.83 (0.73-0.94)

0.005

0.82 (0.72-0.94)

<0.001

100-149

0.63 (0.55-0.72)

<0.001

0.63 (0.55-0.73)

<0.001

150-249

0.44 (0.39-0.50)

<0.001

0.45 (0.39-0.51)

<0.001

250+

0.37 (0.31-0.45)

<0.001

0.38 (0.32-0.46)

<0.001

World Health Organization Stage at ART initiation

Stage 1

1.00

Stage 2

0.99 (0.67-1.47)

0.957

Stage 3

2.04 (1.38-3.03)

<0.001

Stage 4

3.78 (2.52-5.67)

<0.001